HUP0301390A3 - Oral pharmaceutical composition containing valsartan - Google Patents

Oral pharmaceutical composition containing valsartan

Info

Publication number
HUP0301390A3
HUP0301390A3 HU0301390A HUP0301390A HUP0301390A3 HU P0301390 A3 HUP0301390 A3 HU P0301390A3 HU 0301390 A HU0301390 A HU 0301390A HU P0301390 A HUP0301390 A HU P0301390A HU P0301390 A3 HUP0301390 A3 HU P0301390A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
oral pharmaceutical
containing valsartan
valsartan
Prior art date
Application number
HU0301390A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0301390A2 publication Critical patent/HUP0301390A2/hu
Publication of HUP0301390A3 publication Critical patent/HUP0301390A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0301390A 2000-06-22 2001-06-20 Oral pharmaceutical composition containing valsartan HUP0301390A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (2)

Publication Number Publication Date
HUP0301390A2 HUP0301390A2 (hu) 2003-11-28
HUP0301390A3 true HUP0301390A3 (en) 2005-04-28

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301390A HUP0301390A3 (en) 2000-06-22 2001-06-20 Oral pharmaceutical composition containing valsartan

Country Status (21)

Country Link
EP (2) EP2072049A3 (OSRAM)
JP (3) JP2003535895A (OSRAM)
KR (2) KR100659644B1 (OSRAM)
CN (2) CN100450478C (OSRAM)
AU (2) AU2001285768B2 (OSRAM)
BR (1) BR0111868A (OSRAM)
CA (1) CA2411882C (OSRAM)
CZ (1) CZ20024180A3 (OSRAM)
EC (1) ECSP024389A (OSRAM)
HK (1) HK1052868A1 (OSRAM)
HU (1) HUP0301390A3 (OSRAM)
IL (2) IL153428A0 (OSRAM)
MX (1) MXPA02012683A (OSRAM)
NO (1) NO20026123L (OSRAM)
NZ (2) NZ522953A (OSRAM)
PL (1) PL358290A1 (OSRAM)
RU (1) RU2333757C2 (OSRAM)
SG (1) SG162605A1 (OSRAM)
SK (1) SK18062002A3 (OSRAM)
WO (1) WO2001097805A2 (OSRAM)
ZA (1) ZA200210359B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281978T3 (es) * 1998-12-23 2007-10-01 Novartis Ag Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2.
EP1467728B1 (en) * 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
AU2005318365B2 (en) 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
FI963611A0 (fi) 1994-03-17 1996-09-13 Ciba Geigy Ag Diabeettisen munuaissairauden hoito valsartaanilla
ATE209047T1 (de) * 1995-06-07 2001-12-15 Searle & Co Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
US6174910B1 (en) * 1996-02-29 2001-01-16 Novartis Ag AT1 receptor antagonist for the stimulation of apoptosis
DE69726729T2 (de) * 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
ES2281978T3 (es) * 1998-12-23 2007-10-01 Novartis Ag Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2.
AR032152A1 (es) * 2000-04-12 2003-10-29 Novartis Ag Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica

Also Published As

Publication number Publication date
HK1083452A1 (zh) 2006-07-07
RU2333757C2 (ru) 2008-09-20
CA2411882C (en) 2011-09-06
EP2072049A3 (en) 2009-12-30
IL153428A (en) 2013-12-31
CN1679551A (zh) 2005-10-12
HK1052868A1 (zh) 2003-10-03
CZ20024180A3 (cs) 2003-04-16
KR100659644B1 (ko) 2006-12-21
ECSP024389A (es) 2003-02-06
ZA200210359B (en) 2003-11-13
NZ522953A (en) 2005-10-28
AU8576801A (en) 2002-01-02
HUP0301390A2 (hu) 2003-11-28
NO20026123L (no) 2003-02-18
SK18062002A3 (sk) 2003-07-01
BR0111868A (pt) 2003-07-01
JP2007091758A (ja) 2007-04-12
KR100525341B1 (ko) 2005-11-02
CN1221256C (zh) 2005-10-05
IL153428A0 (en) 2003-07-06
NZ540748A (en) 2007-04-27
EP1296677A2 (en) 2003-04-02
MXPA02012683A (es) 2003-04-25
PL358290A1 (en) 2004-08-09
NO20026123D0 (no) 2002-12-19
CN100450478C (zh) 2009-01-14
CN1437469A (zh) 2003-08-20
JP2012211200A (ja) 2012-11-01
EP2072049A2 (en) 2009-06-24
WO2001097805A3 (en) 2002-08-29
SG162605A1 (en) 2010-07-29
CA2411882A1 (en) 2001-12-27
WO2001097805A2 (en) 2001-12-27
AU2001285768B2 (en) 2005-03-10
KR20050085978A (ko) 2005-08-29
JP2003535895A (ja) 2003-12-02
KR20030019450A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
EG24357A (en) New Pharmaceutical composition
IL152659A0 (en) Pharmaceutical composition
EG23943A (en) Flash-melt oral dosage formulation
SI1524266T1 (sl) Farmacevtski sestavek
GB0028575D0 (en) Oral pharmaceutical compositions containing cyclodextrins
HUP0204555A3 (en) Pharmaceutical composition
HUP0004989A3 (en) Extended release oral dosage composition
HUP0202495A3 (en) Stable medicinal compositions for oral use
HUP0301390A3 (en) Oral pharmaceutical composition containing valsartan
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
HUP0400850A3 (en) Oral pharmaceutical compositions
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
IL154238A0 (en) Pharmaceutical composition
GB0016067D0 (en) Oral compositions
HUP0203383A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
GB0022297D0 (en) Oral compositions
GB0005382D0 (en) Pharmaceutical composition
EP1210935A4 (en) DRUGS FOR ORAL USE
AU2001278788A1 (en) Oral composition
AU2001278487A1 (en) Oral composition
AU8254101A (en) Medicinal compositions
HUP0301891A3 (en) Oral composition
AU2001239349A1 (en) Oral pharmaceutical compositions containing n-sulphonylindoline derivatives
AU5978900A (en) Oral composition comprising capsules
PL358275A1 (en) Oral pharmaceutical compositions containing terbinafine

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal